From Yahoo Finance: 2025-03-30 16:12:00

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the top mid cap biotech stocks to buy, with a market cap of $7.15 billion and 60 hedge fund holders. The company focuses on developing precision oncology treatments and ended fiscal Q4 2024 with $2.3 billion in cash and investments. Analysts are optimistic, with a median price target of $38.45, indicating an 85.96% upside potential.

Jared Holz, a Mizuho health care equity strategist, discussed the oversaturation in the biotech sector on CNBC’s ‘Power Lunch.’ With nearly 700-800 biotech stocks in the market, a quarter have enterprise values in negative territory. Holz suggests focusing on assets not currently owned to create value and reduce the number of biotech companies with negative values.

Investors and analysts are searching for a clear pathway for biotech to perform better. Holz emphasized the need to dissolve biotech stocks with negative values and return cash to shareholders. The sector poses high risks and rewards, with potential stock surges or plunges based on clinical trial outcomes. Single stock picking remains crucial in making money in the biotech sector.



Read more at Yahoo Finance: Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?